Immutep Limited Long-Term Debt 2011-2026 | IMMP

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Immutep Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	8.79 M	7.64 M	6.65 M	5.78 M	5.03 M	-	-	-	-	-

All numbers in AUD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.79 M	5.03 M	6.78 M

Quarterly Long-Term Debt Immutep Limited

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	80.1 K	-	-	-	133 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in AUD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
133 K	80.1 K	107 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	130 K	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	52.5 M	$ 33.23	-4.03 %	$ 584 M	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	93.3 M	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	137 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	8.76 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	12.7 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	118 M	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	2.01 B	$ 64.66	-1.37 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	171 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	78.5 M	-	-4.8 %	$ 255 M	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	467 K	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Avid Bioservices CDMO	54.2 M	-	-	$ 789 M	USA
Certara CERT	290 M	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	2.47 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	137 K	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	437 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	1.49 M	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	2.35 M	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Codexis CDXS	28.9 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Corvus Pharmaceuticals CRVS	1.37 M	$ 17.75	-0.79 %	$ 852 M	USA
CTI BioPharma Corp. CTIC	47.9 M	-	-	$ 1.2 B	USA
CohBar CWBR	349 K	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	37 K	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	37 K	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	22.4 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	5.62 M	$ 20.02	-4.67 %	$ 3.29 B	USA
AgeX Therapeutics AGE	13.2 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	5.38 M	$ 17.54	-3.36 %	$ 450 M	USA
Evofem Biosciences EVFM	8 K	-	7.55 %	$ 38.1 M	USA